Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

NCT06962137 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer Adenocarcinoma Metastatic
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: zolbetuximab
OTHER: Retrospective cohort, no intervention

Sponsor

Universitaire Ziekenhuizen KU Leuven